Authors


Faiyaz Syed, MD, MPH

Latest:

Barriers and Facilitators to Managing Social Care in the Digital Era Among Michigan Health Centers

There is widespread interest in understanding the role of health care in meeting social needs. This study examines community-wide activities, resources, and information technology used to manage social care.


Cynthia Moreau, PharmD, BCACP, CPh

Latest:

Provider Perceptions of Pharmacists in Primary Care–Based Accountable Care Organizations

In this article, the authors describe their experiences addressing provider perceptions and methods to overcome several challenges to clinical pharmacist integration in primary care–based accountable care organizations.


Robert M. Rifkin, MD, FACP

Latest:

Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

Robert M. Rifkin, MD, FACP, discusses how the MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition sheds light on elranatamab’s role in relapsed/refractory multiple myeloma while panelists discuss how emerging data on bispecific antibodies and combination strategies could shape treatment timing and improve outcomes, especially in heavily pretreated patients.


Amy McMichael, MD

Latest:

Discussing the Pathophysiology of Alopecia Areata

Panelists discuss how alopecia areata (AA) is a chronic autoimmune disease characterized by inflammation that attacks hair follicles, leading to hair loss and varying disease progression.


Abigail Wiser, BS

Latest:

Addressing the Opioid Crisis

The authors highlight the diversity of multiagency electronic data-sharing approaches and present a case study addressing the opioid crisis


Hyun Kyung Chun, PharmD

Latest:

Hospital Outcomes of Male Breast Cancer in the United States

This is the first study to estimate the hospital lengths of stay and costs of male breast cancer at the US population level.


Alison M. Edwards | Image Credit: © Symphony Health, an ICON plc company
Alison M. Edwards

Latest:

Contributor: Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.


Soleyah Groves, MD

Latest:

Service Line Care Delivery Model for COVID-19 Patient-Centric Care

The authors provide steps hospitals can take to align their care delivery model to effectively meet the demands of a public health crisis such as the current pandemic.


Lisa Engel, MA, BA

Latest:

Implementing Multistate Behavioral Health Pay-for-Performance Initiatives in Medicaid Managed Care

The authors describe a pay-for-performance initiative targeting behavioral health providers, which was introduced by a large Medicaid managed care organization across multiple states.


Rita de Cassia Castro, MD

Latest:

Baloxavir vs Oseltamivir: Reduced Utilization and Costs in Influenza

Baloxavir, compared with oseltamivir, was associated with lower health care resource utilization and costs in patients with influenza, particularly those at high risk of secondary complications.


Stephen Schondelmeyer, PharmD, PhD

Latest:

Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.



Jean Feng, PhD

Latest:

Reducing Readmissions in the Safety Net Through AI and Automation

Artificial intelligence (AI) and electronic health record–based automation tools helped a safety-net health system meet performance-based readmission metrics, thereby retaining critical funding while improving clinical and equity outcomes.


Martine C. Maculaitis, PhD

Latest:

Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice

Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.


Joseph R. Betancourt, MD, MPH

Latest:

Addressing Virtual Care Disparities for Patients With Limited English Proficiency

With increased use of virtual care due to the COVID-19 pandemic, the following recommendations address disparities for patients with limited English proficiency.


Enrico Repetto, MD

Latest:

Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes

Analysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.


Margaret I. Liang, MD, MS

Latest:

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.


Jill Feldman

Latest:

Adverse Effect Management in the COCOON Trial for EGFR-Mutated NSCLC: Jill Feldman

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.


Parul Mistry, MD, MA

Latest:

Predicting Opioid Use Disorder and Associated Risk Factors in a Medicaid Managed Care Population

A Medicaid managed care organization developed a machine learning model to identify opioid use disorder (OUD) risk factors and predict OUD incidence in its multistate population.


Lindsay Dymowski

Latest:

Contributor: How Pharmacists and Providers Can Improve Patient Care

Pharmacists and pharmacies can be doing more to help with medication management for their patients.


Dr Matthew Matasar | Image Credit: Rutgers Cancer Institute
Matthew Matasar, MD

Latest:

Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress

At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.



Jonathan T. Rawlins, MA

Latest:

Improving Pain Clinic Outcomes With Preappointment Surveys: Data-Driven Policy Change

Implementing a policy change to require preappointment surveys before scheduling initial clinic evaluations can improve wait-list times and show rates.


Deborah R. Kaye, MD, MS

Latest:

Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs

The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.


Andrew D. Schreiner, MD, MSCR

Latest:

Statin Prescribing Patterns in Patient-Centered Medical Home Patients With NAFLD

In this study, authors assessed the proportion of patients with nonalcoholic fatty liver disease (NAFLD) receiving prescriptions for statins in primary care.


James Motyka, PharmD

Latest:

Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications

The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.


Sunny C. Lin, PhD, MS

Latest:

Bundled Payments Lead to Quality Improvements in Hospitals’ Skilled Nursing Facility Referral Networks

The Bundled Payments for Care Improvement program was associated with improved quality of skilled nursing facilities in hospital referral networks for patients undergoing surgery for joint replacement.


Arshad Rahim, MD, MBA

Latest:

Stakeholder Insights on rtCGM in T2D Population Health Management

Leading payer and health system stakeholders reviewed literature and shared insights on the value of real-time continuous glucose monitoring (rtCGM) in type 2 diabetes (T2D) population health.


Carolina Schinke, MD

Latest:

Diving Deeper: Long-Term Safety With Talquetamab

A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, emphasizing the promising efficacy and improved safety profile of GPRC5D-targeting agents, the importance of patient-specific factors in therapy selection, and the role of prophylactic measures to manage infection risks, supporting personalized treatment strategies.


John Allan, MD

Latest:

Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

Panelists share their final thoughts on bispecific therapies in B-cell lymphomas based on insights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo